Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33586770.
- Also identified by DOI 10.1093/infdis/jiaa223 and PMC identifier 7883023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HIV-infected individuals successfully controlling viral replication via antiretroviral therapy often have a compromised HIV-specific T-cell immune response due to the lack of CD4 T-cell help, viral escape, T-cell exhaustion, and reduction in numbers due to the withdrawal of cognate antigen. A successful HIV cure strategy will likely involve a durable and potent police force that can effectively recognize and eliminate remaining virus that may emerge decades after an individual undergoes an HIV cure regimen. T cells are ideally suited to serve in this role, but given the state of the HIV-specific T-cell response, it is unclear how to best restore HIV-specific T-cell activity prior initiation of a HIV cure strategy. Here, we review several strategies of generating HIV-specific T cells ex vivo that are currently being tested in the clinic and discuss how infused T cells can be part of an HIV cure strategy.
Medical subject headings
- Adoptive Transfer
- CD4-Positive T-Lymphocytes
- HIV Infections
- HIV-1